Literature DB >> 10644756

Platelet-derived growth factor and lysophosphatidic acid inhibit growth hormone binding and signaling via a protein kinase C-dependent pathway.

L Rui1, S F Archer, L S Argetsinger, C Carter-Su.   

Abstract

Growth hormone (GH) regulates body growth and metabolism. GH exerts its biological action by stimulating JAK2, a GH receptor (GHR)-associated tyrosine kinase. Activated JAK2 phosphorylates itself and GHR, thus initiating multiple signaling pathways. In this work, we demonstrate that platelet-derived growth factor (PDGF) and lysophosphatidic acid (LPA) down-regulate GH signaling via a protein kinase C (PKC)-dependent pathway. PDGF substantially reduces tyrosyl phosphorylation of JAK2 induced by GH but not interferon-gamma or leukemia inhibitory factor. PDGF, but not epidermal growth factor, decreases tyrosyl phosphorylation of GHR (by approximately 90%) and the amount of both total cellular GHR (by approximately 80%) and GH binding (by approximately 70%). The inhibitory effect of PDGF on GH-induced tyrosyl phosphorylation of JAK2 and GHR is abolished by depletion of 4beta-phorbol 12-myristate 13-acetate (PMA)-sensitive PKCs with chronic PMA treatment and is severely inhibited by GF109203X, an inhibitor of PKCs. In contrast, extracellular signal-regulated kinases 1 and 2 and phosphatidylinositol 3-kinase appear not to be involved in this inhibitory effect of PDGF. LPA, a known activator of PKC, also inhibits GH-induced tyrosyl phosphorylation of JAK2 and GHR and reduces the number of GHR. We propose that ligands that activate PKC, including PDGF, LPA, and PMA, down-regulate GH signaling by decreasing the number of cell surface GHR through promoting GHR internalization and degradation and/or cleavage of membrane GHR and release of the extracellular domain of GHR.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10644756     DOI: 10.1074/jbc.275.4.2885

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  3 in total

1.  Mutations in PNPLA6 are linked to photoreceptor degeneration and various forms of childhood blindness.

Authors:  S Kmoch; J Majewski; V Ramamurthy; S Cao; S Fahiminiya; H Ren; I M MacDonald; I Lopez; V Sun; V Keser; A Khan; V Stránecký; H Hartmannová; A Přistoupilová; K Hodaňová; L Piherová; L Kuchař; A Baxová; R Chen; O G P Barsottini; A Pyle; H Griffin; M Splitt; J Sallum; J L Tolmie; J R Sampson; P Chinnery; E Banin; D Sharon; S Dutta; R Grebler; C Helfrich-Foerster; J L Pedroso; D Kretzschmar; M Cayouette; R K Koenekoop
Journal:  Nat Commun       Date:  2015-01-09       Impact factor: 14.919

2.  Imatinib Inhibits GH Secretion From Somatotropinomas.

Authors:  Prakamya Gupta; Ashutosh Rai; Kanchan Kumar Mukherjee; Naresh Sachdeva; Bishan Das Radotra; Raj Pal Singh Punia; Rakesh Kumar Vashista; Debasish Hota; Anand Srinivasan; Sivashanmugam Dhandapani; Sunil Kumar Gupta; Anil Bhansali; Pinaki Dutta
Journal:  Front Endocrinol (Lausanne)       Date:  2018-08-27       Impact factor: 5.555

3.  SH2-B promotes insulin receptor substrate 1 (IRS1)- and IRS2-mediated activation of the phosphatidylinositol 3-kinase pathway in response to leptin.

Authors:  Chaojun Duan; Minghua Li; Liangyou Rui
Journal:  J Biol Chem       Date:  2004-08-16       Impact factor: 5.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.